questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Phosphotransferases (Phosphate Group Acceptor)
Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Phosphotransférases
Tests de laboratoire
Phosphotransférases
Symptômes métaboliques
Phosphotransférases
Tests génétiques
Phosphotransférases
Imagerie médicale
Phosphotransférases
Symptômes
5
Fatigue
Phosphotransférases
Troubles neurologiques
Phosphotransférases
Enzymes
Phosphotransférases
Symptômes néonatals
Phosphotransférases
Retard de développement
Phosphotransférases
Prévention
5
Prévention
Phosphotransférases
Dépistage néonatal
Phosphotransférases
Recommandations diététiques
Phosphotransférases
Conseils génétiques
Phosphotransférases
Vaccination
Phosphotransférases
Traitements
5
Traitement nutritionnel
Phosphotransférases
Thérapie génique
Phosphotransférases
Médicaments
Phosphotransférases
Essais cliniques
Phosphotransférases
Gestion diététique
Phosphotransférases
Complications
5
Complications métaboliques
Phosphotransférases
Troubles cardiaques
Phosphotransférases
Qualité de vie
Phosphotransférases
Complications
Phosphotransférases
Maladies métaboliques
Phosphotransférases
Facteurs de risque
5
Facteurs de risque
Phosphotransférases
Facteurs environnementaux
Phosphotransférases
Maladies auto-immunes
Phosphotransférases
Alimentation
Phosphotransférases
Infections
Phosphotransférases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adenylate kinase",
"alternateName": "Adenylate Kinase",
"url": "https://questionsmedicales.fr/mesh/D000263",
"about": {
"@type": "MedicalCondition",
"name": "Adenylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D000263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "ATP synthetase complexes",
"alternateName": "ATP Synthetase Complexes",
"url": "https://questionsmedicales.fr/mesh/D025181",
"about": {
"@type": "MedicalCondition",
"name": "ATP synthetase complexes",
"code": {
"@type": "MedicalCode",
"code": "D025181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Guanylate kinase",
"alternateName": "Guanylate Kinases",
"url": "https://questionsmedicales.fr/mesh/D051528",
"about": {
"@type": "MedicalCondition",
"name": "Guanylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D051528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside diphosphate kinase",
"alternateName": "Nucleoside-Diphosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009701",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside diphosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NM23 Nucleoside Diphosphate kinases",
"alternateName": "NM23 Nucleoside Diphosphate Kinases",
"url": "https://questionsmedicales.fr/mesh/D054778",
"about": {
"@type": "MedicalCondition",
"name": "NM23 Nucleoside Diphosphate kinases",
"code": {
"@type": "MedicalCode",
"code": "D054778",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside phosphate kinase",
"alternateName": "Nucleoside-Phosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009703",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside phosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.575"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"alternateName": "Phosphotransferases (Phosphate Group Acceptor)",
"code": {
"@type": "MedicalCode",
"code": "D017856",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch."
}
},
{
"@type": "Person",
"name": "Zengqi Xie",
"url": "https://questionsmedicales.fr/author/Zengqi%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China."
}
},
{
"@type": "Person",
"name": "Bernhard Erni",
"url": "https://questionsmedicales.fr/author/Bernhard%20Erni",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Yulin Zhu",
"url": "https://questionsmedicales.fr/author/Yulin%20Zhu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
},
{
"@type": "Person",
"name": "Feng He",
"url": "https://questionsmedicales.fr/author/Feng%20He",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel.",
"datePublished": "2022-06-24",
"url": "https://questionsmedicales.fr/article/35885925",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes13071142"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.",
"datePublished": "2023-09-17",
"url": "https://questionsmedicales.fr/article/37717927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nano.2023.102707"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.",
"datePublished": "2022-10-01",
"url": "https://questionsmedicales.fr/article/36231056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells11193094"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.",
"datePublished": "2023-02-14",
"url": "https://questionsmedicales.fr/article/36788648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14795"
}
},
{
"@type": "ScholarlyArticle",
"name": "Paclitaxel extravasation treated with systemic corticosteroids.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/35906023",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ced.15348"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"item": "https://questionsmedicales.fr/mesh/D017856"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Paclitaxel#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphotransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphotransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à la naissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en phosphotransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être établies pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions."
}
},
{
"@type": "Question",
"name": "Comment la gestion diététique aide-t-elle ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiaques sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
3 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.
Guangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology, Shenzhen 518055, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Hoffmann Institute of Advanced Materials, Shenzhen Polytechnic University, 7098 Liuxian Blvd, District Nanshan, Shenzhen, 518055, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
Center of Materials Science and Optoelectronics Engineer, University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
Center of Materials Science and Optoelectronics Engineer, University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Center for Advanced Low-Dimension Materials, State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai 201620, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices and State Key Laboratory of Luminescent Materials and Devices, South China University of Technology, Guangzhou 510640, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan h-sugi@dokkyomed.ac.jp.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology, Assam University, Silchar, Assam, India.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
In cervical cancer chemotherapy, paclitaxel (PTX) chemoresistance has become a major difficulty, and it also affects the survival rate of numerous tumor patients. Thus, for the reversal of chemoresist...
There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluat...
Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR...
The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant amo...
Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer....
Paclitaxel (PTX) is one of the most efficient drugs for late-stage non-small cell lung cancer (NSCLC) patients. However, most patients gradually develop resistance to PTX with long-term treatments. Th...
This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus platinum-based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) ...
Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patien...
All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530-2.63...
It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC....
Chemotherapy extravasation is a rare but severe cutaneous complication associated with administration of intravenous chemotherapy. Extravasation causes serious disability and diminishes the quality of...
Hypothesis The study aimed to use molecular hybridization of a cationic lipid with a known pharmacophore to produce a bifunctional lipid having a cationic charge to enhance fusion with the cancer cell...
Apatinib, an oral antiangiogenic drug, exerts potential anti-tumour effects on platinum-resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib p...
This retrospective cohort study reviewed 70 PROC patients who received apatinib plus paclitaxel (apatinib plus paclitaxel group) (N = 32) or paclitaxel monotherapy (paclitaxel monotherapy group) (N = ...
Disease control rate was elevated (84.4% vs. 60.5%, P = 0.028), whereas objective response rate only disclosed an increasing trend (lacked statistical significance) (37.5% vs. 18.4%, P = 0.074) in apa...
Apatinib plus paclitaxel exhibits better efficacy and acceptable toxicity compared with paclitaxel monotherapy in PROC patients....
Although paclitaxel is a promising first-line chemotherapeutic drug for ovarian cancer, acquired resistance to paclitaxel is one of the leading causes of treatment failure, limiting its clinical appli...
Human ovarian cancer cell lines MES and its PTX-resistant counterpart MES-TP cell lines were used and were treated with Asparagus officinalis and paclitaxel alone as well as in combination. Cell proli...
In this study, we found that Asparagus officinalis combined with low-dose paclitaxel synergistically inhibited cell proliferation, induced cellular stress and apoptosis and reduced cell invasion in pa...
These findings suggest that the combination of Asparagus officinalis and paclitaxel have potential clinical implications for development as a novel ovarian cancer treatment strategy....
This study aimed to assess the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metast...
Between October 2020 and March 2022, consecutive patients with diagnosed with metastatic or recurrent cervical cancer were retrospectively recruited in our hospital. Fifty-four patients were treated w...
The nab-paclitaxel group showed a higher ORR than the paclitaxel group both in the raw dataset (72.2% vs. 45.8%; P = 0.025) and matched dataset (81.1% vs. 47.6%; P = 0.008). The median PFS was signifi...
Compared with paclitaxel plus platinum, nab-paclitaxel plus platinum may be an effective and tolerable option as first-line therapy for patients with metastatic or recurrent cervical cancer....
The facile availability of nanoformulations with enhanced antitumor performance remains a big challenge. Herein, we synthesize paclitaxel prodrugs with amphiphilic structures and robust assembling abi...